New research on the treatment of small HER2-positive breast cancers.
作者信息
Krop Ian E
机构信息
Dana-Farber Cancer Institute, Boston, Massachusetts.
出版信息
Clin Adv Hematol Oncol. 2014 Feb;12(2):124-7.
PMID:24892258
Abstract
摘要
相似文献
1
New research on the treatment of small HER2-positive breast cancers.
Clin Adv Hematol Oncol. 2014 Feb;12(2):124-7.
2
Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.
Clin Adv Hematol Oncol. 2016 Jul;14(7):520-30.
3
HER2-directed therapy: current treatment options for HER2-positive breast cancer.
Breast Cancer. 2015 Mar;22(2):101-16. doi: 10.1007/s12282-015-0587-x. Epub 2015 Jan 30.
4
Treating the HER2 pathway in early and advanced breast cancer.
Hematol Oncol Clin North Am. 2013 Aug;27(4):751-65, viii. doi: 10.1016/j.hoc.2013.05.007.
5
Current and future anti-HER2 therapy in breast cancer.
J BUON. 2013 Jan-Mar;18(1):4-16.
6
Improving treatment of HER2-positive cancers: opportunities and challenges.
Sci Transl Med. 2012 Mar 28;4(127):127rv2. doi: 10.1126/scitranslmed.3001539.
7
[Strategies of breast cancer treatment based on determination of biological subtype].
Vopr Onkol. 2011;57(5):542-52.
8
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
Cancer Treat Rev. 2010 Nov;36 Suppl 3:S62-6. doi: 10.1016/S0305-7372(10)70022-0.
9
[Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
Internist (Berl). 2006 Nov;47(11):1183-5. doi: 10.1007/s00108-006-1720-x.
10
Patients with anti-HER2 responsive disease: definition and adjuvant therapies.
Breast. 2011 Oct;20 Suppl 3:S132-4. doi: 10.1016/S0960-9776(11)70310-1.
Zotero 插件